VSTM Q2 2025 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-78.6% YoY

Gross Profit

$2M79.1% margin

Operating Income

-$44M-2047.9% margin

Net Income

-$26M-1213.6% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$196M

Total Liabilities

$160M

Stockholders' Equity

$36M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$10M	-78.6%
Gross Profit	$2M	$10M	-83.1%
Operating Income	-$44M	-$18M	-139.4%
Net Income	-$26M	-$8M	-214.1%

Revenue Segments

Government rebates and other incentives

$338,00086%

Trade discounts and allowances

$29,0007%

Returns

$26,0007%